Drugs / GSK3882347
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05760261 | Apr 2023 → Aug 2024 | urinary tract infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT05138822 | May 2022 → Dec 2024 | urinary tract infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT04488770 | Aug 2020 → May 2021 | urinary tract infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3882347 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04488770 ↗ |
| Route | Oral | “In this single ascending dose phase, participants will receive GSK3882347 50 milligram (mg), 150 mg and 250 mg orally on Day 1 of period 1, 2 and 3 respectively.” NCT04488770 ↗ |
| Target | CYP3A4 | “as an inducer of Cytochrome P450 3A4 (CYP3A4)” NCT05760261 ↗ |